| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/17/2009 | CA2727141A1 Compositions and methods for modulating nicotinic/nmda receptor function |
| 12/17/2009 | CA2727086A1 Compositions and methods for modulating d1-d2 dopamine receptor interaction and function |
| 12/17/2009 | CA2727082A1 Suppression of neuroendocrine diseases |
| 12/17/2009 | CA2726092A1 Suppression of cancers |
| 12/17/2009 | CA2726076A1 Peptide analogs of alpha-melanocyte stimulating hormone |
| 12/17/2009 | CA2725530A1 Nanoparticles containing a peptide, vectors containing the same and pharmaceutical uses of said nanoparticles and said vectors |
| 12/17/2009 | CA2725243A1 Opiorphin for use as a psychostimulant agent |
| 12/17/2009 | CA2724694A1 Compositions and methods for using cells to treat heart tissue |
| 12/17/2009 | CA2723995A1 Compounds for treating symptoms associated with parkinson's disease |
| 12/17/2009 | CA2723991A1 Compounds for treating diseases |
| 12/17/2009 | CA2723967A1 Compounds for treating amyloidoses |
| 12/17/2009 | CA2723824A1 Biocompatible and biodegradable elastomeric polymers |
| 12/17/2009 | CA2723270A1 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
| 12/16/2009 | EP2133419A1 Process for the preparation of dipeptides from cyanophycin employing the isolated Pseudomonas alcaligenes DIP1 CGPase CphEal |
| 12/16/2009 | EP2133098A1 G-CSF conjugates |
| 12/16/2009 | EP2133095A1 Pharmaceutical composition |
| 12/16/2009 | EP2133094A1 Pharmaceutical composition |
| 12/16/2009 | EP2133092A1 Oral vaccine |
| 12/16/2009 | EP2133091A2 Compositions comprising supramolecular insulin assemblies useful for the treatment of diabetes |
| 12/16/2009 | EP2133090A1 Growth hormone secretion stimulator |
| 12/16/2009 | EP2133073A1 Poly(lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar |
| 12/16/2009 | EP2132314A2 Variant activin receptor polypeptides and uses thereof |
| 12/16/2009 | EP2132224A1 Cyclic receptor-associated protein (rap) peptides |
| 12/16/2009 | EP2132222A1 Anti diabetic protein |
| 12/16/2009 | EP2132221A1 Template-fixed peptidomimetics |
| 12/16/2009 | EP2132220A1 Integrin targeted cyclopeptide ligands, their preparation and use |
| 12/16/2009 | EP2132219A2 Ace-inhibitory peptides from whey and methods for providing the same. |
| 12/16/2009 | EP2131864A2 Angiogenic composition |
| 12/16/2009 | EP2131855A2 A conjugate of insulin and vitamin b12 for oral delivery |
| 12/16/2009 | EP2131854A1 Use of lhrh antagonists for the treatment of lower urinary tract symptoms, in particular overactive bladder and/or detrusor overactivity |
| 12/16/2009 | EP2131853A1 Methods and compounds for modulating inflammatory processes |
| 12/16/2009 | EP2131852A1 Treatment of inflammation and/or endotoxic shock |
| 12/16/2009 | EP2131851A1 Nell-1 enhanced bone mineralization |
| 12/16/2009 | EP2131815A1 Coacervation process |
| 12/16/2009 | EP1636593B9 Modulating the interaction between hgf beta chain and c-met |
| 12/16/2009 | EP1597381B1 Production of modified glycoproteins having multiple antennary structures |
| 12/16/2009 | EP1521832B1 Anti-fragilis antibody and uses thereof |
| 12/16/2009 | EP1494539B1 Cheese capable of disinfecting helicobacter pylori |
| 12/16/2009 | EP1434603B1 Method of treatment using ligand-immunogen conjugates |
| 12/16/2009 | EP1425028B1 Use of il-18 inhibitors for the treatement or prevention of sepsis |
| 12/16/2009 | EP1407023B1 Group b streptococcus antigens and corresponding dna fragments |
| 12/16/2009 | EP1287147B1 Immunotoxin fusion proteins and means for expression thereof |
| 12/16/2009 | EP0996455B1 Alpha-o-linked glycoconjugates with clustered (2,6)-st epitopes, methods of preparation and uses thereof |
| 12/16/2009 | CN101605900A Lactococcus promoters and uses thereof |
| 12/16/2009 | CN101605811A Treatment of cachexia |
| 12/16/2009 | CN101605806A Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl- d-tryptophan |
| 12/16/2009 | CN101605557A Use of the endoglycosidase endos for treating immunoglobulin g mediated diseases |
| 12/16/2009 | CN101605556A TRKB agonists for treating autoimmune disorders |
| 12/16/2009 | CN101605555A Medicaments and proteins based on TGF-beta monomers for the treatment of wounds |
| 12/16/2009 | CN101605554A Intracerebral oxidation inhibitor and use thereof |
| 12/16/2009 | CN101605534A A spinal nucleus pulposus implant |
| 12/16/2009 | CN101605532A Protein formulations containing sorbitol |
| 12/16/2009 | CN101605530A Pharmaceutical formulations and methods for making the same |
| 12/16/2009 | CN101603042A RNA interference target for treating hepatitis B virus infection |
| 12/16/2009 | CN101603034A CHO cell line expressing bovine beta interferon and application thereof |
| 12/16/2009 | CN101603033A CHO cell line expressing bovine beta interferon and application thereof |
| 12/16/2009 | CN101603032A CHO cell line expressing porcine beta interferon and application thereof |
| 12/16/2009 | CN101602803A Preparation method of recombination human thymosin beta 16 |
| 12/16/2009 | CN101602801A Polyethyleneglycol modificatory tecombined human granulocyte colony stimulating factor mutant |
| 12/16/2009 | CN101602799A Quick preparation method for protogenic antibacterial polypeptide in cicer arietinum |
| 12/16/2009 | CN101602796A Selenium-containing active polypeptide, preparing method and application thereof |
| 12/16/2009 | CN101602795A Cyclohexalipopeptide amine antifungal compound, salts and preparation method thereof |
| 12/16/2009 | CN101602793A Immunoregulatory polypeptide for preventing and/or treating rheumatoid arthritis and application thereof |
| 12/16/2009 | CN101602792A Novel antibacterial lipopeptid and preparation and application thereof |
| 12/16/2009 | CN101601861A Chronic rheumatoid arthritis therapy containing il-6 antagonist as effective component |
| 12/16/2009 | CN101601859A Application of nattokinase in preparing cerebral protective agent type drugs |
| 12/16/2009 | CN101601858A Application of midkine protein and medical device containing protein |
| 12/16/2009 | CN101601857A Use of low-dose erythropoietin for stimulating endothelial precursor cells, regenerating organs, and slowing down progression of end organ damages |
| 12/16/2009 | CN101601856A Application of actinomycin compound actinomycin V in preparing drugs for anti liver cancer |
| 12/16/2009 | CN101601659A Glutathione enteric-coated pellet and preparation method thereof |
| 12/16/2009 | CN101601646A Nasal cavity drop for treating diabetes and preparation method thereof |
| 12/16/2009 | CN100569798C GLP-1 derivative |
| 12/16/2009 | CN100569797C Undecapeptide and application thereof |
| 12/16/2009 | CN100569796C Immune modulating peptide |
| 12/16/2009 | CN100569795C Oxidation resistance zymolyte rich in pollen active peptide |
| 12/16/2009 | CN100569297C Gene transfer-mediated angiogenesis therapy |
| 12/16/2009 | CN100569284C Capsules of multienzyme combination |
| 12/16/2009 | CN100569283C Calcium-tablet for preventing osteoporosis |
| 12/16/2009 | CN100569282C Injection bone peptide freeze-drying preparation and its making method |
| 12/16/2009 | CN100569281C Preparation and use of compositions for treating and preventing necrosis |
| 12/15/2009 | US7632933 Corticotropin releasing factor 2 receptor agonists |
| 12/15/2009 | US7632925 Antibodies that bind human 17-A1/EpCAM tumor antigen |
| 12/15/2009 | US7632919 Polystyrene binding peptides and methods of use |
| 12/15/2009 | US7632918 Semi-synthetic glycopeptides with antibiotic activity |
| 12/15/2009 | US7632819 Administering a peptide, Asparagine-Isoleucine-Proline-Asparagine (SEQ ID NO: 5),to inhibit oxidative stress mediating neurodegenerative diseases; antiapoptosis; Alzheimer's, Parkinson's, and Huntington diseases; amyotrophic lateral sclerosis;antiischemic, -inflammatory agents; stroke, cardiovascular |
| 12/15/2009 | US7632818 Method for treating conditions associated with the Metabolic Syndrome (Syndrome X) |
| 12/15/2009 | US7632817 Antibodies against exogeneous protein; epitopes different from those detected by antibodies; myasthenia gravis; infertility; gene therapy |
| 12/15/2009 | US7632816 Treatment of Alzheimer amyloid deposition |
| 12/15/2009 | US7632815 Treating or preventing myocardial contractile dysfunction that occurs after a myocardial infarction or other structural heart disease (e.g., end-stage valve disease) by by administering CaMK11 inhibitor, a peptide having a specific sequence of amino acids; dilated cardiomyopathy; transgenic animals |
| 12/15/2009 | US7632814 HYD1 peptides as anti-cancer agents |
| 12/15/2009 | US7632813 Administering N-(3-{2-[3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-tetrahydro-2H-pyran-4-ylpropyl)cycloheptanecarboxamideas an inhibitor and a type of parathyroid hormone to treat and/orprevent bone metabolic diseases |
| 12/15/2009 | US7632812 Methods to stimulate insulin production by pancreatic β-cells |
| 12/15/2009 | US7632811 A polypeptide produced by the parathyroid glands using such analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis |
| 12/15/2009 | US7632810 Inducing proliferation of lymphoid lineage progenitor cells or progeny bywith Bv8 or a mixture of Bv8 and endothelial growth factor, EG-VEGF; increasing the population of T lymphocytes and CD4 antigen, white blood cells followingimmunosuppressant therapy; HIV |
| 12/15/2009 | US7632809 Multimeric ligands with enhanced stability |
| 12/15/2009 | US7632808 Use of MP52 or MP121 for the treatment and prevention of diseases of the nervous system |
| 12/15/2009 | US7632807 Cyclosporin alkynes and their utility as pharmaceutical agents |
| 12/15/2009 | US7632806 Stabilized pharmaceutical peptide compositions |
| 12/15/2009 | US7632805 Administering a biodrug comprising a growth factor binding compounds having a central non-peptide organic scaffold, such as a calix[4]arene, to which arelinked cyclic tetrapeptides; angiogenesis inhibiters; antitumor agents; solid tumors;anticarciogenic agents; restenosis |
| 12/15/2009 | US7632804 Dietary products comprising one or more of γ-polyglutamic acid (γ-PGA, H form) and γ-polyglutamates for use as nutrition supplements |